Brief: Guardant Health Announces Approval In Europe Of Guardant360® Cdx
08/10/2026 23:20
BRIEF-Guardant Health Announces Approval In Europe Of Guardant360® Cdx Oct 8 (Reuters) - Guardant Health, Inc. GH.O:
GUARDANT HEALTH ANNOUNCES APPROVAL IN EUROPE OF GUARDANT360® CDX AS COMPANION DIAGNOSTIC FOR ASTRAZENECA’S ETCAMAH™ (CAMIZESTRANT) IN ADVANCED ER-POSITIVE BREAST CANCER
Source text: ID:nBwbqjLxja
Further company coverage: GH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Guardant Health
See all newsBrief: Guardant Health Announces Approval In Europe Of Guardant360® Cdx
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
US Health Secretary Kennedy Jr. adds eight new members to key health committee (updated)
Brief: US FDA Grants Accelerated Approval To Etcamah For Advanced Breast Cancer With ESR1 Mutation
Brief: Guardant Health To Appeal Federal District Court Judgment